# DPYD

Source: https://onco.cc/targets/dpyd/  
OnCo record `dpyd` (Target). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

DPYD (Dihydropyrimidine dehydrogenase [NADP(+)]) is an enzyme. The public catalogues list it as a drug target and a biomarker, and an approved or late-stage drug is recorded against it. Tied to Head and neck squamous cell carcinoma and Gastric & gastro-oesophageal junction cancer.

## Summary

Catalyses the reduction of uracil and thymine in the initial step of reductive pyrimidine catabolism, a pathway that yields beta-alanine from uracil and beta-aminoisobutyrate from thymine. Also capable of degrading the chemotherapeutic drug 5-fluorouracil.

CIViC holds 4 clinical evidence items and 0 assertions across 4 variants, naming Fluorouracil, Capecitabine, Tegafur and Leucovorin. Open Targets scores its association with cancer at 0.68 (direct and indirect evidence; datatypes clinical 0.94, affected pathway 0.94, literature 0.87, genetic association 0.33, somatic mutation 0.23, animal model 0.38).

## Fields

- Kind: Target
- Last checked: 2026-09-23
- Also known as: dihydropyrimidine dehydrogenase; Dihydropyrimidine dehydrogenase [NADP(+)]; DHPDHase
- Tags: cancer-genes-wave
- Symbol: DPYD
- Class: enzyme
- Biology: Catalyses the reduction of uracil and thymine in the initial step of reductive pyrimidine catabolism, a pathway that yields beta-alanine from uracil and beta-aminoisobutyrate from thymine. Also capable of degrading the chemotherapeutic drug 5-fluorouracil. Location: Cytoplasm, cytosol (UniProt). Locus 1p21.3 (HGNC).
- Where found: Head and neck squamous cell carcinoma: CIViC evidence names this disease; Gastric & gastro-oesophageal junction cancer: Open Targets association 0.54 with gastric cancer (MONDO_0001056)

## Notes

- Written by scripts/fetch-cancer-genes.ts from CIViC, Open Targets, IntOGen, HGNC and UniProt; the function text is UniProt's, condensed and in UK spelling. Roles: Open Targets known-drug datatype score 0.94; CIViC holds 4 clinical evidence items on its variants. Evidence tier "approved-drug" is the strongest of those signals.
- Prevalence not recorded: none of the sources gives a positivity rate.

## Sources

- HGNC HGNC:3012: https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:3012
- UniProt Q12882: https://www.uniprot.org/uniprotkb/Q12882/entry
- NCBI Gene 1806: https://www.ncbi.nlm.nih.gov/gene/1806
- Ensembl ENSG00000188641: https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000188641

## Connected records

- collections: [CIViC](https://onco.cc/collections/civic/), [Open Targets Platform](https://onco.cc/collections/open-targets/)
- cancers: [Gastric & gastro-oesophageal junction cancer](https://onco.cc/cancers/gastric/), [Head and neck squamous cell carcinoma](https://onco.cc/cancers/head-and-neck/)

---
JSON: https://onco.cc/api/v1/entities/dpyd.json